SCHEMBL3923381

SCHEMBL3923381

COP(C)(=O)Oc1ccc2[nH]nc(-c3cc4ccccc4[nH]3)c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITK Q08881 19/20 0.59
▸ FGFR1 P11362 1/20 0.54
▸ PLK4 O00444 1/20 0.47
▸ CHEK1 O14757 1/20 0.47
▸ AURKA O14965 1/20 0.47
▸ CCNB2 O95067 1/20 0.47
▸ ABL1 P00519 1/20 0.47
▸ CDK1 P06493 1/20 0.47
▸ PDGFRB P09619 1/20 0.47
▸ CDK4 P11802 1/20 0.47
▸ SRC P12931 1/20 0.47
▸ CCNB1 P14635 1/20 0.47
▸ CCNA2 P20248 1/20 0.47
▸ CCND1 P24385 1/20 0.47
▸ CDK2 P24941 1/20 0.47
▸ WEE1 P30291 1/20 0.47
▸ TTK P33981 1/20 0.47
▸ KDR P35968 1/20 0.47
▸ FLT3 P36888 1/20 0.47
▸ NEK2 P51955 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3923370 0.90 ITK (0.62) ITKFGFR1PLK4CHEK1AURKA
SCHEMBL3920812 0.87 ITK (0.59) ITKFGFR1PLK4CHEK1AURKA
SCHEMBL3923266 0.86 ITK (0.56) ITKFGFR1PLK4CHEK1AURKA
SCHEMBL3923060 0.86 ITK (0.56) ITKFGFR1PLK4CHEK1AURKA
SCHEMBL3926018 0.86 ITK (0.56) ITKFGFR1PLK4CHEK1AURKA
SCHEMBL3920798 0.86 ITK (0.58) ITKFGFR1
SCHEMBL3919180 0.85 ITK (0.56) ITKFGFR1
SCHEMBL3924166 0.85 ITK (0.56) ITKFGFR1PLK4CHEK1AURKA
SCHEMBL3919611 0.83 ITK (0.58) ITKFGFR1
SCHEMBL3928741 0.83 ITK (0.54) ITKFGFR1PLK4CHEK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732938-B1 ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2009-05-06 — — EP claimed
US-7491710-B2 Organophosphorus derivatives of indazoles and use thereof as medicinal products AVENTIS PHARMA S.A. (FR) 2009-02-17 — — US claimed
EP-1732938-B1 ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2009-05-06 — — EP disclosed
US-7491710-B2 Organophosphorus derivatives of indazoles and use thereof as medicinal products AVENTIS PHARMA S.A. (FR) 2009-02-17 — — US disclosed
US-7491710-B2 Organophosphorus derivatives of indazoles and use thereof as medicinal products AVENTIS PHARMA S.A. (FR) 2009-02-17 — — US disclosed
EP-1732938-A1 ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS Aventis Pharma S.A. (FR) 2006-12-20 — — EP disclosed
WO-2005058923-A1 ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2005-06-30 — — WO disclosed
US-20050137171-A1 Novel organophosphorus derivatives of indazoles and use thereof as medicinal products AVENTIS PHARMA S.A. (FR) 2005-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137171-A1 Novel organophosphorus derivatives of indazoles and use thereof as medicinal products PPIP5K2, INPPL1, IP6K3 ITK 1443/4885FGFR1 4023/4885PLK4 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback